# Phase II/III of Recombinant Human Serum Albumin

> **NCT05858853** · PHASE2,PHASE3 · COMPLETED · sponsor: **Protgen Ltd** · enrollment: 92 (actual)

## Conditions studied

- Cirrhotic Ascites

## Interventions

- **DRUG:** Recombinant Human Serum Albumin
- **DRUG:** Recombinant Human Serum Albumin
- **DRUG:** Human serum albumin
- **DRUG:** Human serum albumin

## Key facts

- **NCT ID:** NCT05858853
- **Lead sponsor:** Protgen Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-24
- **Primary completion:** 2023-09-15
- **Final completion:** 2023-09-15
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05858853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05858853, "Phase II/III of Recombinant Human Serum Albumin". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05858853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*